Drugs / rAAV2/5-PBGD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02082860 | Nov 2012 → Jul 2014 | acute intermittent porphyria | Digna Biotech S.L. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV2/5-PBGD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02082860 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “the safety of a recombinant adeno-associated vector expressing PBGD (rAAV2/5-PBGD)” PMID 27212246 ↗ May 2016 |
| Route | Intravenous | “four cohorts of 2 patients each received a single intravenous injection of the vector” PMID 27212246 ↗ May 2016 |